Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults

Étude du portage rhinopharyngé de Streptococcus pneumoniae et de sa sensibilité aux antibiotiques chez les enfants en bonne santé âgés de moins de 2ans dans la région de Marrakech (Maroc)

(2011) M. Bouskraoui et al.   ARCHIVES DE PEDIATRIE

Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States

(2011) J. B. Rosen et al.   CLINICAL INFECTIOUS DISEASES

Review on the immunogenicity and safety of PCV-13 in infants and toddlers

(2011) Marta C Nunes et al.   Expert Review of Vaccines

Novel Protein-Based Pneumococcal Vaccines Administered with the Th1-Promoting Adjuvant IC31 Induce Protective Immunity against Pneumococcal Disease in Neonatal Mice

(2011) Thorunn Asta Olafsdottir et al.   INFECTION AND IMMUNITY

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

(2011) David R. Strutton et al.   JOURNAL OF INFECTION

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

(2011) Elizabeth Miller et al.   LANCET INFECTIOUS DISEASES

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine

(2011) Robert Frenck et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Risk of Red Queen dynamics in pneumococcal vaccine strategy

(2011) Johanna M.C. Jefferies et al.   TRENDS IN MICROBIOLOGY

Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy

(2011) Sara Boccalini et al.   VACCINE

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina

(2011) Analía Urueña et al.   VACCINE

The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America

(2011) Norberto Giglio et al.   VACCINE

Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US

(2011) K.M. Shea et al.   VACCINE

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine

(2011) Francisco Gimenez-Sanchez et al.   VACCINE

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway

(2011) Bjarne Robberstad et al.   VACCINE

Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine

(2011) Janusz Gadzinowski et al.   VACCINE

Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children

(2011) Anna S. Tocheva et al.   VACCINE

Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose

(2011) K.P. Klugman et al.   VACCINE

Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model

(2011) Julie M. Skinner et al.   VACCINE

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A

(2011) David Cooper et al.   VACCINE

Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older

(2011) H. Lode et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants

(2011) E. Grimprel et al.   VACCINE

A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years

(2011) T.F. Schwarz et al.   VACCINE

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

(2011) Elizabeth Miller et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan

(2011) Li-Min Huang et al.   VACCINE

Immunization with the RrgB321 fusion protein protects mice against both high and low pilus-expressing Streptococcus pneumoniae populations

(2011) Monica Moschioni et al.   VACCINE

Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study

(2011) Stefan Flasche et al.   PLOS MEDICINE

Economic evaluation of pneumococcal conjugate vaccination in The Gambia

(2010) Sun-Young Kim et al.   BMC INFECTIOUS DISEASES

Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers

(2010) S. Esposito et al.   Clinical and Vaccine Immunology

Safety and Immunogenicity of Coadministering a Combined Meningococcal Serogroup C andHaemophilus influenzaeType b Conjugate Vaccine with 7-Valent Pneumococcal Conjugate Vaccine and Measles, Mumps, and Rubella Vaccine at 12 Months of Age

(2010) Elizabeth Miller et al.   Clinical and Vaccine Immunology

Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle‐Aged and Older Adults

(2010) Daniel M. Musher et al.   JOURNAL OF INFECTIOUS DISEASES

PavB is a surface-exposed adhesin of Streptococcus pneumoniae contributing to nasopharyngeal colonization and airways infections

(2010) Inga Jensch et al.   MOLECULAR MICROBIOLOGY

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults

(2010) Neil French et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microbial Interactions in the Respiratory Tract

(2010) Timothy F. Murphy et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

(2010) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Carried Pneumococci in Massachusetts Children

(2010) William P. Hanage et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

(2010) S. H. Yeh et al.   PEDIATRICS

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries

(2010) Sandra E. Talbird et al.   VACCINE

Clinical and economic burden of pneumococcal disease in older US adults

(2010) Derek Weycker et al.   VACCINE

Control of Streptococcus pneumoniae serotype 5 epidemic of severe pneumonia among young army recruits by mass antibiotic treatment and vaccination

(2010) Ran D. Balicer et al.   VACCINE

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

(2010) Jaime L. Rubin et al.   VACCINE

GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis

(2010) Ying-Jie Lu et al.   VACCINE

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

(2010) Dorothee M. Kieninger et al.   VACCINE

Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project

(2010) Hope L. Johnson et al.   PLOS MEDICINE

Superior Immune Response to Protein-Conjugate versus Free Pneumococcal Polysaccharide Vaccine in Chronic Obstructive Pulmonary Disease

(2009) Mark T. Dransfield et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae

(2009) Dylan R Pillai et al.   BMC GENOMICS

Efficacy of pneumococcal vaccination in adults: a meta-analysis

(2009) A. Huss et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection

(2009) J. Cao et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

(2009) David Goldblatt et al.   CLINICAL INFECTIOUS DISEASES

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: A new simulation model

(2009) Philippe De Wals et al.   CLINICAL THERAPEUTICS

Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines

(2009) Daniel J. Isaacman et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

(2009) Katherine L O'Brien et al.   LANCET

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, Canada

(2009) I. Feavers et al.   VACCINE

Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

(2009) Angelique G.S.C. Jansen et al.   VACCINE

Emergence ofStreptococcus pneumoniaeSerotypes 19A, 6C, and 22F and Serogroup 15 in Cleveland, Ohio, in Relation to Introduction of the Protein‐Conjugated Pneumococcal Vaccine

(2008) Michael R. Jacobs et al.   CLINICAL INFECTIOUS DISEASES

Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection

(2008) Lisa A. Jackson et al.   CLINICAL INFECTIOUS DISEASES

Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological Memory

(2008) Andrés de Roux et al.   CLINICAL INFECTIOUS DISEASES

Initial and Subsequent Response to Pneumococcal Polysaccharide and Protein‐Conjugate Vaccines Administered Sequentially to Adults Who Have Recovered from Pneumococcal Pneumonia

(2008) Daniel M. Musher et al.   JOURNAL OF INFECTIOUS DISEASES

Increase in the Prevalence of the Newly Discovered Pneumococcal Serotype 6C in the Nasopharynx after Introduction of Pneumococcal Conjugate Vaccine

(2008) Moon H. Nahm et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia

(2008) M. Saaka et al.   VACCINE